AbbVie Inc. Shows Promise Amid Mixed Market Performance
Valued at a market cap of $336 billion, AbbVie Inc. (ABBV) is a leading global biopharmaceutical company focused on developing innovative therapies for complex health issues. Based in North Chicago, Illinois, AbbVie emphasizes research-driven solutions in various fields, including immunology, oncology, and neuroscience, positively impacting millions of patients worldwide.
Market Performance Overview
Over the past 52 weeks, AbbVie’s stock performance has lagged behind the broader market. While ABBV has increased 12.6% during this period, the S&P 500 Index ($SPX) has seen a more substantial 21.8% gain. However, in 2025 alone, AbbVie’s shares have risen by 6.9%, surpassing SPX’s 2.7% increase year-to-date.
Comparative Analysis with the Pharmaceuticals Sector
Focusing on narrower metrics, AbbVie outperformed the Vaneck Pharmaceutical ETF (PPH), which reported a modest 3.1% gain in the past year.
Strong Q4 Earnings Report
AbbVie shares rose 4.7% on Jan. 31 following the release of its Q4 earnings results. Revenue increased by 5.6% year-over-year, reaching $15.1 billion and exceeding analyst expectations of $14.82 billion. However, adjusted EPS came in at $2.16, missing consensus estimates by 4.3%. The company anticipates a full-year 2025 adjusted diluted EPS in the range of $12.12 to $12.32.
Positive Outlook for Skyrizi and Rinvoq
AbbVie has raised its 2027 sales projections for Skyrizi and Rinvoq to over $31 billion, representing an increase of $4 billion from prior guidance. Expectations are that Skyrizi will generate over $20 billion, while Rinvoq is anticipated to exceed $11 billion in sales.
Analysts’ Expectations for 2024
For the current fiscal year, set to conclude in December, analysts predict that AbbVie’s EPS will increase 22.6% year-over-year to $12.41 per share. Notably, AbbVie has demonstrated a strong track record, beating consensus estimates in each of the last four quarters.
Consensus Ratings from Analysts
Among the 26 analysts covering AbbVie, the current consensus rating is a “Moderate Buy.” This assessment is based on 16 “Strong Buy” ratings, two “Moderate Buys,” and eight “Holds.”
Price Target Adjustments
This consensus is a slight decline from three months earlier, when there were 17 “Strong Buy” ratings. On Feb. 3, Truist raised AbbVie’s price target from $211 to $217 while maintaining a “Buy” rating, citing the company’s strong Q4 results and promising growth trajectory through 2029.
The average price target among analysts stands at $204.32, reflecting a potential premium of 7.6% compared to ABBV’s current levels. The highest target reaches $227, suggesting an upside of 19.5% from the present stock price.
On the date of publication, Rashmi Kumari did not hold any positions in the securities mentioned in this article. All data and information provided is for informational purposes only. For more details, please consult the Barchart Disclosure Policy here.
More news from Barchart
The views and opinions expressed herein are those of the author and do not necessarily reflect those of Nasdaq, Inc.
